ROYALTY MONETIZATIONUP TO $60 MILLION
Vafseo (vadadustat) is an oral HIF-PH inhibitor (HIF-PHI) used for the treatment of anemia in CKD patients. HIF-PHIs are based on Nobel Prize-winning science and unlike current standard of care treatments such as erythropoiesis stimulating agents, HIF-PHIs are orally administered and can raise hemoglobin in a more physiologically relevant way. VAFSEO was approved in Japan in June 2020.
HCRx purchased royalties and sales-based milestones, in each case, based primarily on sales in Japan, from Akebia Therapeutics. Akebia is developing vadadustat for the U.S. market, and the company monetized the Japanese royalties to help fund late-stage development and pre-commercial activities.
Note: This transaction also appears in the Royalty Monetization section under VAFSEO.